Engineered immune cells take on relapsed blood cancers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Subjects must meet all of the following criteria to be enrolled: 1. • Aged 18 to 75 years, male or female; 2. • Histologically or cytologically diagnosed with relapsed/refractory CD19-positive hematologic malignancy according to the 2022 World Health Organization (WHO) diagnostic criteria; 3. • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 4. • Life expectancy of at least 3 months; 5. • No contraindications to peripheral blood leukapheresis; 6. • CD19 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry; 7. • No severe cardiac, pulmonary, hepatic, or renal dysfunction; 8. • Able to understand and willing to provide written informed consent. Exclusion Criteria Subjects who meet any of the following criteria should be excluded from enrollment: 1. History of allergy to any component of the cellular product; 2. Complete blood count meeting any of the following criteria: white blood cell count (WBC) ≤1 × 10⁹/L, absolute neutrophil count (ANC) ≤0.5 × 10⁹/L, absolute lymphocyte count (ALC) ≤0.5 × 10⁹/L, or platelet count (PLT) ≤25 × 10⁹/L; 3. Laboratory abnormalities including, but not limited to, serum total bilirubin ≥1.5 mg/dL; serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 times the upper limit of normal; or serum creatinine ≥2.0 mg/dL; 4. Class III or IV cardiac insufficiency according to the New York Heart Association (NYHA) functional classification, or left ventricular ejection fraction (LVEF) \<50% by echocardiography; 5. Abnormal pulmonary function, with oxygen saturation \<92% on room air; 6. History of myocardial infarction, cardiac angioplasty or stent placement, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment; 7. Grade 3 hypertension with poor blood pressure control despite medication; 8. History of traumatic brain injury, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease; 9. Autoimmune disease, immunodeficiency, or other conditions requiring treatment with immunosuppressive agents; 10. Uncontrolled active infection; 11. Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy; 12. Receipt of a live vaccine within 4 weeks prior to enrollment; 13. Positive test results for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status; 14. History of alcohol abuse, drug abuse, or psychiatric illness; 15. Participation in any other clinical study within 3 months prior to enrollment in this clinical study; 16. Female subjects who meet any of the following conditions: 1. Pregnant or breastfeeding; 2. Planning to become pregnant during the study; or 3. Of childbearing potential and unwilling or unable to use effective contraception; 17. Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this study.